Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease

[1]  M. Chesselet,et al.  Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease , 2012, Molecular Neurodegeneration.

[2]  M. Chesselet,et al.  Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease , 2012, Molecular and Cellular Neuroscience.

[3]  J. Hong,et al.  (-)-Epigallocatethin-3-O-gallate counteracts caffeine-induced hyperactivity: evidence of dopaminergic blockade , 2010, Behavioural pharmacology.

[4]  Steven Finkbeiner,et al.  Quantitative Relationships between Huntingtin Levels, Polyglutamine Length, Inclusion Body Formation, and Neuronal Death Provide Novel Insight into Huntington's Disease Molecular Pathogenesis , 2010, The Journal of Neuroscience.

[5]  D. Rubinsztein,et al.  Antioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease , 2010, Human molecular genetics.

[6]  Jane S. Paulsen,et al.  Striatal and white matter predictors of estimated diagnosis for Huntington disease , 2010, Brain Research Bulletin.

[7]  Carlos Cepeda,et al.  Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease , 2010, ASN neuro.

[8]  G. Repovš,et al.  Curcumin Labeling of Neuronal Fibrillar Tau Inclusions in Human Brain Samples , 2010, Journal of neuropathology and experimental neurology.

[9]  Nick C Fox,et al.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data , 2009, The Lancet Neurology.

[10]  F. Gomez-Pinilla,et al.  Dietary curcumin supplementation counteracts reduction in levels of molecules involved in energy homeostasis after brain trauma , 2009, Neuroscience.

[11]  M. Krishna,et al.  Curcumin mediates time and concentration dependent regulation of redox homeostasis leading to cytotoxicity in macrophage cells. , 2009, European journal of pharmacology.

[12]  B. Nannenga,et al.  Conformational Targeting of Fibrillar Polyglutamine Proteins in Live Cells Escalates Aggregation and Cytotoxicity , 2009, PloS one.

[13]  J. Brender,et al.  Determining the effects of lipophilic drugs on membrane structure by solid-state NMR spectroscopy: the case of the antioxidant curcumin. , 2009, Journal of the American Chemical Society.

[14]  Danielle A. Simmons,et al.  Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice , 2009, Proceedings of the National Academy of Sciences.

[15]  M. Chesselet,et al.  Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. , 2009, Human molecular genetics.

[16]  Carlos Cepeda,et al.  Age-Dependent Alterations of Corticostriatal Activity in the YAC128 Mouse Model of Huntington Disease , 2009, The Journal of Neuroscience.

[17]  M. Chesselet,et al.  Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice , 2008, Neuroscience.

[18]  G. Bates,et al.  Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease , 2008, Molecular Neurodegeneration.

[19]  Giovanni Coppola,et al.  The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice , 2008, Proceedings of the National Academy of Sciences.

[20]  Dongsun Park,et al.  Antiteratogenic effect of resveratrol in mice exposed in utero to 2,3,7,8-tetrachlorodibenzo-p-dioxin. , 2008, European journal of pharmacology.

[21]  Takashi Morihara,et al.  Curcumin Structure-Function, Bioavailability, and Efficacy in Models of Neuroinflammation and Alzheimer's Disease , 2008, Journal of Pharmacology and Experimental Therapeutics.

[22]  S. Sang,et al.  Bioavailability issues in studying the health effects of plant polyphenolic compounds. , 2008, Molecular nutrition & food research.

[23]  Bruce Fischl,et al.  Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. , 2008, Brain : a journal of neurology.

[24]  B. Aggarwal,et al.  Curcumin as "Curecumin": from kitchen to clinic. , 2008, Biochemical pharmacology.

[25]  V. Mok,et al.  Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. , 2008, Journal of clinical psychopharmacology.

[26]  A. Morton,et al.  Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death , 2008, Brain Research Bulletin.

[27]  Alun Williams,et al.  Ginkgolides protect against amyloid-β1–42-mediated synapse damage in vitro , 2008, Molecular Neurodegeneration.

[28]  Jane S. Paulsen,et al.  Detection of Huntington’s disease decades before diagnosis: the Predict-HD study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[29]  Jane S. Paulsen,et al.  Psychiatric Symptoms in Huntington’s Disease before Diagnosis: The Predict-HD Study , 2007, Biological Psychiatry.

[30]  V. Mok,et al.  Curcumin effects on blood lipid profile in a 6-month human study. , 2007, Pharmacological research.

[31]  J. Cha,et al.  Transcriptional signatures in Huntington's disease , 2007, Progress in Neurobiology.

[32]  Nihal Ahmad,et al.  Dose translation from animal to human studies revisited , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  Mauro Delorenzi,et al.  Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood , 2007, Proceedings of the National Academy of Sciences.

[34]  B. Hyman,et al.  Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model , 2007, Journal of neurochemistry.

[35]  Elizabeth H. Aylward,et al.  Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease , 2007, Brain Research Bulletin.

[36]  David S Tuch,et al.  Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures , 2006, Movement disorders : official journal of the Movement Disorder Society.

[37]  S. Moncada,et al.  Nitric oxide, cell bioenergetics and neurodegeneration , 2006, Journal of neurochemistry.

[38]  A. Al-Majed,et al.  Immediate and Delayed Treatments with Curcumin Prevents Forebrain Ischemia-Induced Neuronal Damage and Oxidative Insult in the Rat Hippocampus , 2006, Neurochemical Research.

[39]  N. Nukina,et al.  Curcumin enhances the polyglutamine-expanded truncated N-terminal huntingtin-induced cell death by promoting proteasomal malfunction. , 2006, Biochemical and biophysical research communications.

[40]  B. Tripathy,et al.  Neuroprotective and Anti-ageing Effects of Curcumin in Aged Rat Brain Regions , 2006, Biogerontology.

[41]  A. Singh,et al.  Multiple biological activities of curcumin: a short review. , 2006, Life sciences.

[42]  J. Olson,et al.  Regional and cellular gene expression changes in human Huntington's disease brain. , 2006, Human molecular genetics.

[43]  J. Sutcliffe,et al.  Selective deficits in the expression of striatal‐enriched mRNAs in Huntington's disease , 2006, Journal of neurochemistry.

[44]  F. Gomez-Pinilla,et al.  Dietary curcumin counteracts the outcome of traumatic brain injury on oxidative stress, synaptic plasticity, and cognition , 2006, Experimental Neurology.

[45]  J. Cryan,et al.  The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice , 2005, Neuroscience & Biobehavioral Reviews.

[46]  Fusheng Yang,et al.  Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions , 2005, Neurobiology of Aging.

[47]  Alexander Gerhard,et al.  Microglial activation in presymptomatic Huntington's disease gene carriers. , 2005, Brain : a journal of neurology.

[48]  M. Chesselet,et al.  Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing , 2005, Neurobiology of Disease.

[49]  Fusheng Yang,et al.  Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo* , 2005, Journal of Biological Chemistry.

[50]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[51]  A. Tobin,et al.  A cell-based screen for drugs to treat Huntington's disease , 2004, Neurobiology of Disease.

[52]  M. Beal,et al.  Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease , 2004, Experimental Neurology.

[53]  D. Borchelt,et al.  Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice , 2004, Experimental Neurology.

[54]  N. Nukina,et al.  Inhibition of Proteasomal Function by Curcumin Induces Apoptosis through Mitochondrial Pathway* , 2004, Journal of Biological Chemistry.

[55]  Angus C Nairn,et al.  DARPP-32: an integrator of neurotransmission. , 2004, Annual review of pharmacology and toxicology.

[56]  Elizabeth Evans,et al.  Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. , 2003, Human molecular genetics.

[57]  M. Chesselet,et al.  Time course of early motor and neuropathological anomalies in a knock‐in mouse model of Huntington's disease with 140 CAG repeats , 2003, The Journal of comparative neurology.

[58]  Junying Yuan,et al.  Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders , 2003, Nature.

[59]  Joel S Perlmutter,et al.  Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. , 2002, Archives of neurology.

[60]  M. Chesselet,et al.  Early Motor Dysfunction and Striosomal Distribution of Huntingtin Microaggregates in Huntington's Disease Knock-In Mice , 2002, The Journal of Neuroscience.

[61]  G. Cole,et al.  The Curry Spice Curcumin Reduces Oxidative Damage and Amyloid Pathology in an Alzheimer Transgenic Mouse , 2001, The Journal of Neuroscience.

[62]  G. M. Cole,et al.  Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology , 2001, Neurobiology of Aging.

[63]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[64]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[65]  L. Howells,et al.  Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. , 2001, Cancer research.

[66]  R. Albin,et al.  Neurological abnormalities in a knock-in mouse model of Huntington's disease. , 2001, Human molecular genetics.

[67]  R H Myers,et al.  Quantitative neuropathological changes in presymptomatic Huntington's disease , 2001, Annals of neurology.

[68]  C. Skibola,et al.  Guest Editors: Enrique Cadenas and Kelvin J. A. Davies POTENTIAL HEALTH IMPACTS OF EXCESSIVE FLAVONOID INTAKE , 2000 .

[69]  M. Chesselet,et al.  Decrease in Striatal Enkephalin mRNA in Mouse Models of Huntington’s Disease , 2000, Experimental Neurology.

[70]  M. MacDonald,et al.  Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. , 2000, Human molecular genetics.

[71]  Jen-kun Lin,et al.  Biotransformation of curcumin through reduction and glucuronidation in mice. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[72]  Steven Finkbeiner,et al.  Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions , 1998, Cell.

[73]  S. W. Davies,et al.  Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[74]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[75]  R. Porsolt,et al.  Depression: a new animal model sensitive to antidepressant treatments , 1977, Nature.

[76]  M. Chesselet,et al.  Mouse Models of Mental Illness and Neurological Disease , 2012 .

[77]  Charles Watson,et al.  The Mouse Nervous System. , 2012 .

[78]  J. Lucas,et al.  Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. , 2011, Brain : a journal of neurology.

[79]  F. Sullivan,et al.  A two generation reproductive toxicity study with curcumin, turmeric yellow, in Wistar rats. , 2007, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[80]  B. Aggarwal,et al.  From kitchen to clinic , 2007 .

[81]  B. Thierry,et al.  The tail suspension test: A new method for screening antidepressants in mice , 2004, Psychopharmacology.

[82]  V. S. Murthy,et al.  Reproductive response of rats fed turmeric (Curcuma longa L.) and its alcoholic extract , 1987 .